Please assess the completion status of the following clinical trial:

Trial Title: Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 18 years of age,~* Must have an FEV1 of \> 70% of predicted,~* Must have evidence of bronchial hyperreactivity to methacholine as defined by a methacholine provocation causing a 20% or greater fall in FEV1 (PC20) \< 8 mg/ml~* Use of inhaled steroid is permitted; however, no change in inhaled steroid dosage will be permitted over the duration of study~* Must have a normal platelet count,~* Must be willing to and competent to sign the consent form~Exclusion Criteria:~* Subjects that do not have allergic asthma will be excluded.~* Subjects with ER visits or upper respiratory infections within the last six weeks will be excluded.~* Subjects with tobacco use within the past year or \> 10 pack year history of tobacco use will be excluded.~* Subjects with serum IgE levels of less than 30 or greater than 700 Iu/mL will be excluded.~* Subjects that require oral steroid use will be excluded.~* Subjects who weigh \< 30 kg or \> 150 kg are excluded, and subjects with baseline IgE levels greater than 300 may be excluded, depending on weight~* Pregnant or nursing females will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).